about
Efficacy and safety of fixed-dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trialThe Association of Retinopathy and Plasma Glucose and HbA1c: A Validation of Diabetes Diagnostic Criteria in a Chinese PopulationRationale, Design, and Baseline Characteristics of Beijing Prediabetes Reversion Program: A Randomized Controlled Clinical Trial to Evaluate the Efficacy of Lifestyle Intervention and/or Pioglitazone in Reversion to Normal Glucose Tolerance in PrediPatterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany.Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naïve Chinese patients: Analysis of results from the CONSENT trial.Efficacy of metformin in preventing progression to diabetes in a Chinese population with impaired glucose regulation: Protocol for a multicentre, open-label, randomized controlled clinical studyA nationwide assessment of blood pressure control and the associated factors in Chinese type 2 diabetes mellitus patientsUse of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendationsEfficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin-naïve people with type 2 diabetes: The EDITION AP randomized controlled trialA pragmatic study of mid-mixture insulin and basal insulin treatment in patients with type 2 diabetes uncontrolled with oral antihyperglycemic medications: A lesson from real-world experienceSafety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS AsiaFactors and outcomes associated with discontinuation of basal insulin therapy in patients with type 2 diabetes mellitusHigher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: Results of a multicentre, open-label, randomized controlled trial (BEYOND VII)Blood pressure and glucose control and the prevalence of albuminuria and left ventricular hypertrophy in patients with hypertension and diabetes
P50
Q33625563-AE70EFD3-6C6F-4250-8D64-9CBCDE65B637Q37363663-A5C89179-49A5-4687-8DFF-A4D668B62741Q37607425-B115A99D-0F1C-4795-AF21-1F622AD00F80Q38620148-2E19A3C8-5268-4449-AAD9-EA74B382EF68Q48142051-10312EAC-C01E-473D-9535-FACF8C51C496Q90071917-A05355E7-1FAC-47AB-96AF-3D34C141E93BQ90653691-234C60DB-FA4F-4463-9F78-1224B0F7CDE0Q91544396-6F21E0B4-FC30-449D-A3AE-AACB86B0A8F4Q91663359-BB57DED3-CD8E-40A9-967D-60D3E77AAC9CQ91720414-64BF0599-423F-4031-BC09-736828D83471Q92108172-A114DC2A-7074-4520-81D5-940CD02D4BC3Q92136206-C8513D49-E4C9-4CB7-9665-BD3031488CF4Q92685940-9B101561-7446-4FD8-ABD8-2742067CAE00Q92686071-D6701412-C598-4C39-8F5B-0BFE28FA8EAD
P50
description
researcher (ORCID 0000-0003-1305-1598)
@en
name
Linong Ji
@en
type
label
Linong Ji
@en
prefLabel
Linong Ji
@en
P31
P496
0000-0003-1305-1598